Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Price Target at $62.00

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $62.00.

Several analysts have issued reports on CRBP shares. B. Riley lowered their target price on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, September 20th. Mizuho reissued an “outperform” rating and set a $74.00 price objective on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and issued a $82.00 target price on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, September 23rd. Finally, Piper Sandler started coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price objective for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp boosted its stake in shares of Corbus Pharmaceuticals by 34.6% in the 3rd quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company’s stock valued at $12,287,000 after purchasing an additional 153,243 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in Corbus Pharmaceuticals in the second quarter worth $14,267,000. Geode Capital Management LLC boosted its position in Corbus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company’s stock valued at $5,154,000 after buying an additional 18,702 shares during the period. Integral Health Asset Management LLC bought a new position in shares of Corbus Pharmaceuticals during the second quarter valued at about $4,525,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Corbus Pharmaceuticals by 224.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 64,800 shares during the period. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Stock Up 0.1 %

Shares of CRBP opened at $13.17 on Thursday. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $61.90. The stock has a market cap of $160.40 million, a PE ratio of -2.81 and a beta of 2.58. The business’s 50-day moving average price is $16.62 and its 200-day moving average price is $36.01.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.